Henry Tsai

Dr. Tsai completed his combined MD and PhD program (pharmacology and toxicology) at UC Irvine, then went to UCLA for his Anatomic and Clinical Pathology residency program as well as fellowships in Surgical Pathology and Cytopathology. Dr. Tsai is board-certified in Anatomic Pathology, Clinical Pathology, and Cytopathology. He holds New York certificate of qualification in Oncology, Genetic Testing, Virology, Bacteriology, Mycology, Toxicology, Cytology, and Histology. He has authored many publications in peer-reviewed journals, incl. a book chapter in Handbook of Immunohistochemistry and In situ Hybridization of Human Carcinomas.* Previously, Dr. Tsai was the laboratory director of Human Longevity Inc. and its Oncology Division (before acquisition by NeoGenomics). Dr. Tsai was also responsible for the medical directorship of many urologic groups as well as the Medical Director of Houston Plus Diagnostics Laboratory.